Advertisement


Andrew Seidman, MD, and Erica Mayer, MD, MPH, on Results of the PALLAS Clinical Trial

2015 San Antonio Breast Cancer Symposium

Advertisement

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract OT1-03-21)



Related Videos

Breast Cancer

Lisa Carey, MD, and Sibylle Loibl, MD, PhD: Update on Metastatic Disease

Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy,...

Breast Cancer

Andrew Seidman, MD, and Seema Khan, MD, MPH on Controversies in the Management of DCIS

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discuss the session modera...

Breast Cancer

Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study

Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HE...

Breast Cancer

Jack Cuzick, PhD, FMedSci, on DCIS Recurrence Rates: Anastrozole vs Tamoxifen

Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen...

Breast Cancer

Michael Gnant, MD, on Hormone Receptor–Positive Breast Cancer: Results From the ABCSG-18 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in p...

Advertisement

Advertisement



Advertisement